Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Compass Therapeutics, Inc.NONE · Entity 5614 | Director | June 19, 2020 | June 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Compass Therapeutics, Inc.
Report date June 19, 2020 · Filed June 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,502,025 |
Reported balance
After 2020-06-19 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-06-19 · Purchase · Acquired 289,118 · Balance 2,502,025 F1: These shares are held directly by Biomatics Capital Partners, LP. The Reporting Person is a member of the Issuer's board of directors, the co-founder of and a managing partner at Biomatics Capital Partners, and exercises shared voting and investment power of the securities held by Biomatics Capital Partners, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held directly by Biomatics Capital Partners, LP. The Reporting Person is a member of the Issuer's board of directors, the co-founder of and a managing partner at Biomatics Capital Partners, and exercises shared voting and investment power of the securities held by Biomatics Capital Partners, LP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2020 Filed Jun 23, 2020 21:38 UTC | Compass Therapeutics, Inc. NONE · Entity 5614 | PurchaseCommon Stock | 289,118 | $5.00 | $1,445,590.00 |
DisclosureSEC source: 0001213900-20-015639 · ownership.xml · nonDerivative · entry 1 Sunderland Julie · CIK 0001814190 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,502,025 F1 · ownership.nature: These shares are held directly by Biomatics Capital Partners, LP. The Reporting Person is a member of the Issuer's board of directors, the co-founder of and a managing partner at Biomatics Capital Partners, and exercises shared voting and investment power of the securities held by Biomatics Capital Partners, LP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.